Oral irinotecan for treatment of pediatric solid tumors: ready for prime time?
Wagner
Lars M
LM
University of Cincinnati College of Medicine, Cincinnati, OH, USA. lars.wagner@cchmc.org
D000284:Administration, Oral; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D000971:Antineoplastic Combined Chemotherapy Protocols; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D002648:Child; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D000077146:Irinotecan; D020714:Maximum Tolerated Dose
D000972:Antineoplastic Agents, Phytogenic; D000077146:Irinotecan; D002166:Camptothecin